CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms
Standard
CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms. / Merseburger, Axel S; Bannowsky, Andreas; Becker, Klaus; Bokemeyer, Carsten; Eichenauer, Rolf; Lehmann, Jan; Mickisch, Gerald; Steuber, Thomas; von Amsberg, Gunhild; von Kügelgen, Tobias; Wülfing, Christian.
In: AKTUEL UROL, Vol. 2020, 2020.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - CARD-Studie – Bedeutung für die Therapie des fortgeschrittenen Prostatakarzinoms
AU - Merseburger, Axel S
AU - Bannowsky, Andreas
AU - Becker, Klaus
AU - Bokemeyer, Carsten
AU - Eichenauer, Rolf
AU - Lehmann, Jan
AU - Mickisch, Gerald
AU - Steuber, Thomas
AU - von Amsberg, Gunhild
AU - von Kügelgen, Tobias
AU - Wülfing, Christian
N1 - Thieme. All rights reserved.
PY - 2020
Y1 - 2020
N2 - BACKGROUND: Various life-prolonging therapy options are available for the treatment of metastatic castration-resistant prostate cancer (mCRPC).OBJECTIVE: The optimal therapy sequence for mCRPC has been discussed for years. With the final results of the CARD study, important prospective data are available to enlighten the discussion about the therapy sequence.MATERIAL AND METHOD: CARD is a randomised phase IV trial in patients with mCRPC who were previously treated with docetaxel and an anti-androgen receptor (ARTA). The study showed significant efficacy benefits in favour of further treatment with cabazitaxel versus a second ARTA therapy. The study results are presented and discussed in the context of previous study data with regard to their importance for everyday clinical practice.RESULTS: The CARD study data confirm cabazitaxel as an effective therapy option for mCRPC patients previously treated with docetaxel and an ARTA. Cabazitaxel was safe to apply. The study results confirm the cross resistance between the two ARTAs Abiraterone and Enzalutamide.CONCLUSION: In mCRPC patients eligible for chemotherapy, the therapy sequence should be chosen so that the patients also receive cabazitaxel. A direct therapy sequence with two ARTAs should be avoided or, at least, only considered if other substances are contraindicated.
AB - BACKGROUND: Various life-prolonging therapy options are available for the treatment of metastatic castration-resistant prostate cancer (mCRPC).OBJECTIVE: The optimal therapy sequence for mCRPC has been discussed for years. With the final results of the CARD study, important prospective data are available to enlighten the discussion about the therapy sequence.MATERIAL AND METHOD: CARD is a randomised phase IV trial in patients with mCRPC who were previously treated with docetaxel and an anti-androgen receptor (ARTA). The study showed significant efficacy benefits in favour of further treatment with cabazitaxel versus a second ARTA therapy. The study results are presented and discussed in the context of previous study data with regard to their importance for everyday clinical practice.RESULTS: The CARD study data confirm cabazitaxel as an effective therapy option for mCRPC patients previously treated with docetaxel and an ARTA. Cabazitaxel was safe to apply. The study results confirm the cross resistance between the two ARTAs Abiraterone and Enzalutamide.CONCLUSION: In mCRPC patients eligible for chemotherapy, the therapy sequence should be chosen so that the patients also receive cabazitaxel. A direct therapy sequence with two ARTAs should be avoided or, at least, only considered if other substances are contraindicated.
U2 - 10.1055/a-1247-4155
DO - 10.1055/a-1247-4155
M3 - SCORING: Zeitschriftenaufsatz
C2 - 32968994
VL - 2020
JO - AKTUEL UROL
JF - AKTUEL UROL
SN - 0001-7868
ER -
